Camelot Portfolios’s AstraZeneca AZN Stock Holding History

Camelot Portfolios’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-319	Closed	-$49.7K	–	166
2024 Q2	$49.7K	Buy	+319	New	+$48K	0.03%	300
2022 Q2	–	Sell	-3,078	Closed	-$408K	–	216
2022 Q1	$408K	Sell	3,078 -2,616	-46%	-$314K	0.2%	139
2021 Q4	$663K	Buy	5,694 +1,980	+53%	+$233K	0.27%	124
2021 Q3	$446K	Buy	+3,714	New	+$432K	0.23%	123
2016 Q4	–	Sell	-3,350	Closed	-$220K	–	162
2016 Q3	$220K	Sell	3,350 -750	-18%	-$49K	0.12%	135
2016 Q2	$248K	Hold	4,100	–	–	0.14%	120
2016 Q1	$231K	Hold	4,100	–	–	0.14%	124
2015 Q4	$278K	Buy	+4,100	New	+$269K	0.18%	115
2014 Q4	–	Sell	-9,123	Closed	-$652K	–	174
2014 Q3	$652K	Sell	9,123 -991	-10%	-$72.5K	0.38%	76
2014 Q2	$752K	Buy	+10,114	New	+$731K	0.48%	65

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Camelot Portfolios's AZN Position: Q3 2024 in Review

Camelot Portfolios sold out of AstraZeneca (AZN) in Q3 2024, closing a stake of 319 shares — an estimated $49.7K sold.

Camelot Portfolios first reported a position in AZN in Q2 2014 and held it in 10 quarters. The position peaked at $752K in Q2 2014. 1,230 funds tracked by Wall St. Rank hold AZN as of Q3 2024.

Camelot Portfolios reported no remaining AstraZeneca position as of Q3 2024 after selling out during the quarter.
Camelot Portfolios sold 319 AstraZeneca shares in Q3 2024, an estimated $49.7K.
Camelot Portfolios first reported a position in AstraZeneca in Q2 2014 and held it in 10 quarters.
Camelot Portfolios's AstraZeneca position peaked at $752K in Q2 2014.
1,230 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2024.

Based on Camelot Portfolios's 13F filing for Q3 2024, filed 12 Nov 2024.